Wave Life Sciences, Inc. (WVE)
NASDAQ: WVE · Real-Time Price · USD
3.460
-0.010 (-0.29%)
At close: Oct 9, 2026, 4:00 PM EDT
3.484
+0.024 (0.69%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Wave Life Sciences Employees
Wave Life Sciences had 317 employees as of December 31, 2025. The number of employees increased by 29 or 10.07% compared to the previous year. That makes Wave Life Sciences the 23,460th largest employer in the world and 3,032nd in the United States.
Employees
317
Change (1Y)
29
Growth (1Y)
10.07%
Revenue / Employee
$206,218
Profits / Employee
-$638,716
Market Cap
681.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 317 | 29 | 10.07% | 317 | 0 |
| Dec 31, 2024 | 288 | 20 | 7.46% | 287 | 1 |
| Dec 31, 2023 | 268 | 16 | 6.35% | 266 | 2 |
| Dec 31, 2022 | 252 | 14 | 5.88% | 250 | 2 |
| Dec 31, 2021 | 238 | 18 | 8.18% | 235 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Pharming Group | 407 |
| Olema Pharmaceuticals | 150 |
| Prime Medicine | 146 |
| Aura Biosciences | 113 |
| OmniAb | 89 |
| Crescent Biopharma | 69 |
| Zevra Therapeutics | 61 |
WVE News
- 10 days ago - Wave Life Sciences announces FDA feedback supports pathway for WVE-006 - TheFly
- 10 days ago - Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD - GlobeNewsWire
- 10 days ago - Wave Life Sciences initiated with a Buy at Ladenburg - TheFly
- 11 days ago - Wave Life announces GSK’s selection of siRNA program to transition to GSK - TheFly
- 11 days ago - Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development - GlobeNewsWire
- 18 days ago - Wave Life Sciences resumed with a Neutral at JPMorgan - TheFly
- 18 days ago - Wave Life Sciences initiates Phase 2a combination trial of WVE-007 - TheFly
- 18 days ago - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - GlobeNewsWire